The Crisis Before the Crisis
Alzheimer’s disease, characterized by progressive brain atrophy, begins silently: The toxic cascade starts 20–30 years before clinical symptoms appear. The scientific consensus points to soluble Aβ oligomers—not late-stage plaques—as the most toxic species and the true trigger of neurodegeneration. This early-stage crisis, combined with the difficulty of delivering therapeutics through the Blood-Brain Barrier (BBB), is why the current standard-of-care fails. Our platform is designed to address both of these critical gaps.
.jpg)
Our solution is a novel, dual-action cyclic peptide platform. This proprietary technology, founded on the visionary work of Prof. Shai Rahimipour, harnesses patented small molecules, a new chemical entity to create cyclic peptide analogs that target a unique structure of oligomers (Cross beta-sheet).
Solving the BBB Challenge: Unlike large antibody therapies which struggle to penetrate the brain, our small cyclic peptides are structurally engineered for efficient passage across the Blood-Brain Barrier (BBB), ensuring optimal therapeutic concentration at the site of pathology.
Targeting the True Trigger: We intervene at the earliest stage of the disease by neutralizing toxic Aβ oligomers—the species responsible for synaptic dysfunction—preventing their aggregation into late-stage, less harmful plaques.
Theragnostic Potential: Our molecular logic allows the same platform to be used for both early diagnostic imaging (to detect oligomer burden) and therapeutic intervention, enabling smarter, mechanism-based treatment strategies.
